Status:

COMPLETED

Comparison of Pharmacokinetic, Safety, Tolerability of Alpha-1 MP and Prolastin In Alpha1-antitrypsin Deficient Adults

Lead Sponsor:

Grifols Therapeutics LLC

Conditions:

Alpha 1-Antitrypsin Deficiency

Eligibility:

All Genders

18+ years

Phase:

PHASE3

Brief Summary

The purpose of this clinical study (ChAMP - Comparability pharmacokinetics of Alpha-1 Modified Process) is to compare the pharmacokinetic, safety and tolerability of Alpha-1 Proteinase Inhibitor (Huma...

Detailed Description

The objective of this study is to demonstrate the pharmacokinetic comparability of Alpha-1 MP to Prolastin® in subjects with Alpha1-antitrypsin deficiency. This study is divided into three 8-week tre...

Eligibility Criteria

Inclusion

  • Documented diagnosis of congenital Alpha1-antitrypsin deficiency
  • Must be receiving augmentation therapy with plasma-derived (human) Alpha1-Proteinase Inhibitor (Prolastin®) for at least one month prior to study entry.
  • Signed written informed consent prior to initiation of any study related procedures

Exclusion

  • Females who are pregnant, breast feeding, or if of child-bearing potential, unwilling to practice adequate contraception throughout the study
  • Use of systemic steroids within the 2 weeks prior to receiving study treatment (this does not include the use of inhaled steroids used on a routine or as needed basis).
  • Subjects who have had exacerbations of their disease within one month of trial entry.

Key Trial Info

Start Date :

May 1 2006

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

February 1 2007

Estimated Enrollment :

24 Patients enrolled

Trial Details

Trial ID

NCT00295061

Start Date

May 1 2006

End Date

February 1 2007

Last Update

September 9 2014

Active Locations (8)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 2 (8 locations)

1

National Jewish Medical and Research Center

Denver, Colorado, United States, 80206

2

University of Florida College of Medicine

Gainesville, Florida, United States, 32610-0225

3

University of Miami School of Medicine

Miami, Florida, United States, 33101

4

St Lukes-Roosevelt Hospital Center, New York

New York, New York, United States, 10019

Comparison of Pharmacokinetic, Safety, Tolerability of Alpha-1 MP and Prolastin In Alpha1-antitrypsin Deficient Adults | DecenTrialz